Patents Examined by Shengjun Wang
  • Patent number: 11654132
    Abstract: The invention relates to methods for treating COVID-19 by targeting the inflammasome/caspase1/pyroptosis axis as a key inflammatory pathway. In particular, the invention relates to treating a patient infected with SARS-CoV-2 with an effective amount of one or more compounds that directly or indirectly inhibit one or more pathways of the inflammasome/caspase1/pyroptosis axis.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: May 23, 2023
    Assignee: MEDSTAR HEALTH, INC.
    Inventors: Thomas M. Fishbein, Khalid M. Khan, Alexander H. Kroemer
  • Patent number: 11654133
    Abstract: The present disclosure provides combination therapy using [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate (cenobamate) and one or more antiepileptic drugs for the prevention or treatment of a neurological disorder such as epilepsy.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: May 23, 2023
    Inventors: Marc Kamin, Laurent Vernillet
  • Patent number: 11642340
    Abstract: The present invention includes a method of reducing or inhibiting the kinase activity of C-KIT mutant tyrosine kinase activity in a cell or a subject, and the use of such compound for treating mutant C-KIT driven cell proliferative disorder(s) in a subject related to using a compound of the present invention: or pharmaceutically acceptable salt thereof, wherein the C-KIT mutation is located in at least one of exon 8, exon 9, exon 11, exon 13, exon 14, or exon 17.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: May 9, 2023
    Inventor: Vinay K. Jain
  • Patent number: 11633371
    Abstract: The present disclosure provides compositions comprising deuterated forms of acetaminophen. When administered to human subjects, such compositions form less of the toxic metabolite NAPQI, and therefore are useful in methods of treating various diseases and conditions with a reduced risk of liver injury or other side effects associated with non-deuterated forms of acetaminophen.
    Type: Grant
    Filed: February 8, 2022
    Date of Patent: April 25, 2023
    Assignee: Lennham Pharmaceuticals, Inc.
    Inventor: Bradford C. Sippy
  • Patent number: 11628163
    Abstract: The present description relates to 1-piperidinepropionic acid or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising it, for use in the treatment of chronic fibrosing diseases.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: April 18, 2023
    Assignee: Università degli Studi di Padova
    Inventors: Patrizia Pontisso, Alessandra Biasiolo, Andrea Cappon, Andrea Martini, Santina Quarta, Mariagrazia Ruvoletto, Cristian Turato, Gianmarco Villano
  • Patent number: 11612578
    Abstract: The invention relates to PUFA, vitamin E, vitamin D and the protein bound amino acids glycine, arginine and tryptophan as active ingredients for use in therapy of patients with sarcopenia and/or frailty or pre-sarcopenic and/or pre-frail patients, wherein an effective amount of said active ingredients is administered in the form of a nutritional composition comprising a) a lipid component providing 40-50 EN % based on the total energy of the nutritional composition, wherein 12-16 EN % based on the total energy of the nutritional composition is provided by PUFA, b) 4.0-8.0 mg/100 mL alpha-TE vitamin E, c) 5.0-12.0 ?g/100 mL vitamin D, d) 2.5-4.5 g/100 mL glycine, e) 0.5-1.5 g/100 mL arginine, and f) at least 0.02 g/100 mL tryptophan.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: March 28, 2023
    Inventors: Edmundo Brito-De-La-Fuente, Ericka Pestana, Stephanie Reichart, Maria Fernanda Martinez-Bock, Sarah Ashley-Maguire, Jose Maria Mainou-Sierra
  • Patent number: 11612609
    Abstract: Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25H-C3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: March 28, 2023
    Assignees: Durect Corporation, Virginia Commonwealth University
    Inventors: Shunlin Ren, Felix Theeuwes, James E. Brown, WeiQi Lin
  • Patent number: 11612572
    Abstract: Disclosed are compositions comprising beta-caryophyllene (BCP) for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using BCP. Disclosed are also compositions comprising CB2 receptor agonists for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using CB2 receptor agonists.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: March 28, 2023
    Inventor: Sharon Anavi-Goffer
  • Patent number: 11596596
    Abstract: Methods of treating neuropathic pain in spinal cord injured individuals by administering levetiracetam or brivaracetam are described.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: March 7, 2023
    Inventor: Scott P. Falci
  • Patent number: 11590110
    Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus using a glycogen synthase kinase 3? inhibitor, such as a glycogen synthase kinase 3? (GSK-3?) or a glycogen synthase kinase 3? (GSK-3?) inhibitor. In some embodiments, the glycogen synthase kinase 3 inhibitor is a glycogen synthase kinase antagonist, e.g., Tideglusib (4-benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione), or a pharmaceutically acceptable salt or derivative thereof. In other embodiments, the glycogen synthase kinase 3 inhibitor is a maleimide-based glycogen synthase kinase 3 inhibitor, e.g., SB-216763 (3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione) or a pharmaceutically acceptable salt or derivative thereof.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: February 28, 2023
    Assignee: The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
    Inventors: Andrea Gramatica, Warner C. Greene
  • Patent number: 11583216
    Abstract: Embodiments of the invention are broadly drawn to methods for determining an optimum dose of an antiarrhythmic drug, for example sotalol. In particular, the method involves titrating the dose of the drug gradually to determine the optimum plasma concentration for a patient, whether the patient has normal or abnormal renal function.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: February 21, 2023
    Assignee: University of Maryland, Baltimore
    Inventors: Vijay Ivaturi, Jogarao Gobburu
  • Patent number: 11576902
    Abstract: The treatment of human subjects suffering from COVID-19 comprises the step of administering to the human subjects a medicament selected from the group consisting of 1,3-bis(7-methoxy-4,9-dihydro-3H-pyrido[3,4-b]indol-1-yl)propane, and/or the isomers, tautomers, enantiomers, esters, derivatives, metal complexes, prodrugs, solvates, metabolites, and pharmaceutically acceptable salts thereof. The medicament may also be contacted with SARS-CoV-2 virus for inhibition of the virus.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: February 14, 2023
    Assignee: Ankh Life Sciences Limited
    Inventors: Gene H. Zaid, Robert Preston Moore, Cameron E. West, Jason H. West, Krishna Mohan Donavalli
  • Patent number: 11564405
    Abstract: Methods for reducing the risk of viral infection in animals due to consumption of viral contaminated feed. The methods comprise administering to an animal in need thereof an effective amount of a feed additive, wherein the feed additive comprises a mixture of organic acids. The methods can be used to reduce the risk of infection in animals whose feed may or may not be contaminated with certain viruses.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: January 31, 2023
    Assignee: Novus International, Inc.
    Inventors: Bradley Van Lawrence, Robert Edward Buresh
  • Patent number: 11554174
    Abstract: In one aspect, the present application relates to an aminothiol-conjugate of formula (I): wherein , , R1, R2, R3, m, n, and p are as described above. The present invention also relates to a method of treating a subject in need of aminothiol therapy using an aminothiol-conjugate of formula (I).
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: January 17, 2023
    Inventors: Dale M. Walker, Vernon E. Walker, Tsvetelina I. Lazarova, Steven W. Riesinger
  • Patent number: 11547685
    Abstract: This document provides methods and materials for treating polycystic diseases such as polycystic kidney disease. For example, methods for using a TRPV2 agonist (e.g., probenecid) and optionally a vasopressin receptor antagonist (e.g., tolvaptan) to treat a mammal having polycystic kidney disease (e.g., autosomal dominant polycystic kidney disease) are provided.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: January 10, 2023
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Vicente E. Torres, Fouad T. Chebib, Peter C. Harris, Xiaofang Wang
  • Patent number: 11534442
    Abstract: The present disclosure provides compositions comprising a lyn kinase activator and TRPM8 agonist, and to methods of: reducing blood glucose levels, weight gain, or fat depot levels; treating metabolic syndrome, Syndrome X, obesity, prediabetes, type II diabetes, type I diabetes; treating hypercholesterolemia, hypertension, coronary heart disease, diabetic neuropathy, lipodystrophy, diabetic retinopathy, erectile dysfunction, kidney disease, dyslipidemia, dyslipoproteinemia, a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, or pancreatitis; inducing the beiging of adipocytes; and preventing pancreatic beta cell degeneration.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: December 27, 2022
    Assignees: Melior Pharmaceuticals I, Inc., Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Andrew G. Reaume, Weina Cong, Frank Greenway, Ann Coulter
  • Patent number: 11510902
    Abstract: A method for preventing or treating a non-alcoholic fatty liver disease in a subject who is at risk of suffering from the non-alcoholic fatty liver disease or suffers from the non-alcoholic fatty liver disease, by administering to the subject a composition comprising a therapeutically effective amount of Antrodins.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: November 29, 2022
    Inventors: Chia-Chin Sheu, Tse-Kai Fu
  • Patent number: 11504380
    Abstract: The invention relates to a method of treating cirrhosis which comprises administering to a subject in need thereof lanifibranor or a deuterated derivative thereof.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: November 22, 2022
    Assignee: INVENTIVA
    Inventors: Guillaume Wettstein, Pierre Broqua, Jean-Louis Junien
  • Patent number: 11497746
    Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) a programmed death ligand 1 (PD-L1) inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: November 15, 2022
    Inventors: Steven Norman Quayle, Simon Stewart Jones, Teru Hideshima, Kenneth C. Anderson
  • Patent number: 11497942
    Abstract: The present invention is a cosmetic or dermatological preparation comprising 0.01% by weight to 5% by weight of at least one red light-filtering dye and 0.0001% by weight to 10% by weight of at least one anti-inflammatory active ingredient. The preparation can be used for the prophylaxis and treatment of sun-irritated skin and to aid the body's own repair mechanisms.
    Type: Grant
    Filed: December 3, 2004
    Date of Patent: November 15, 2022
    Assignee: BEIERSDORF AG
    Inventors: Rainer Kröpke, Ludger Kolbe, Anette Bürger, Claudia Mundt